drugset / Trial / NCT03660345

PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME

NCT03660345

Phase 3 Completed 11 enrolled Rush Eye Associates
RandomizedParallel-groupSingle-blindTreatment

Summary

Treatment-naïve subjects with center-involved diabetic macular edema undergoing pars plana vitrectomy with internal limiting membrane peeling will have similar visual outcomes but better anatomical outcomes compared to subjects undergoing intravitreal bevacizumab monotherapy at one year.

Timeline

Start
2018-09-04
Primary completion
2021-05-04
Completion
2021-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic Intravitreal